Phase 3 Libevitug study for chronic HDV infection

This document is a ClinicalTrials.gov registry entry for a Phase 3 interventional study evaluating Libevitug for treatment of chronic HDV infection. The registry entry includes standard trial metadata such as NCT number, study title, and status information. ClinicalTrials.gov is operated by the NIH's National Library of Medicine under the FDAAA 801 mandate (42 CFR Part 11).

Principal investigators and trial sponsors should ensure their trial registration information remains accurate and up to date per FDAAA 801 requirements. Results for applicable trials must be submitted to ClinicalTrials.gov within 12 months of primary completion date. No immediate compliance action is required for this registry entry itself.